These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 28639229)

  • 1. Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.
    Deng R; Lee AP; Maia M; Lim JJ; Burgess T; Horn P; Derby MA; Newton E; Tavel JA; Hanley WD
    Clin Pharmacokinet; 2018 Mar; 57(3):367-377. PubMed ID: 28639229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.
    Deng R; She G; Maia M; Lim JJ; Peck MC; McBride JM; Kulkarni P; Horn P; Castro A; Newton E; Tavel JA; Hanley WD
    J Clin Pharmacol; 2020 Nov; 60(11):1509-1518. PubMed ID: 32621543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
    Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
    McBride JM; Lim JJ; Burgess T; Deng R; Derby MA; Maia M; Horn P; Siddiqui O; Sheinson D; Chen-Harris H; Newton EM; Fillos D; Nazzal D; Rosenberger CM; Ohlson MB; Lambkin-Williams R; Fathi H; Harris JM; Tavel JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection.
    Lim JJ; Nilsson AC; Silverman M; Assy N; Kulkarni P; McBride JM; Deng R; Li C; Yang X; Nguyen A; Horn P; Maia M; Castro A; Peck MC; Galanter J; Chu T; Newton EM; Tavel JA
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32393496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A.
    Gupta P; Kamath AV; Park S; Chiu H; Lutman J; Maia M; Tan MW; Xu M; Swem L; Deng R
    MAbs; 2016 Jul; 8(5):991-7. PubMed ID: 27031797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children.
    Oo C; Barrett J; Hill G; Mann J; Dorr A; Dutkowski R; Ward P
    Paediatr Drugs; 2001; 3(3):229-36. PubMed ID: 11310719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.
    Lim JJ; Derby MA; Zhang Y; Deng R; Larouche R; Anderson M; Maia M; Carrier S; Pelletier I; Girard J; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
    Ali SO; Takas T; Nyborg A; Shoemaker K; Kallewaard NL; Chiong R; Dubovsky F; Mallory RM
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
    Rayner CR; Bulik CC; Kamal MA; Reynolds DK; Toovey S; Hammel JP; Smith PF; Bhavnani SM; Van Wart SA; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3478-87. PubMed ID: 23669386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial.
    Finberg RW; Lanno R; Anderson D; Fleischhackl R; van Duijnhoven W; Kauffman RS; Kosoglou T; Vingerhoets J; Leopold L
    J Infect Dis; 2019 Mar; 219(7):1026-1034. PubMed ID: 30428049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection.
    Lim JJ; Dar S; Venter D; Horcajada JP; Kulkarni P; Nguyen A; McBride JM; Deng R; Galanter J; Chu T; Newton EM; Tavel JA; Peck MC
    Open Forum Infect Dis; 2022 Feb; 9(2):ofab630. PubMed ID: 35106315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.
    Lee N; Hui DS; Zuo Z; Ngai KL; Lui GC; Wo SK; Tam WW; Chan MC; Wong BC; Wong RY; Choi KW; Sin WW; Lee EL; Tomlinson B; Hayden FG; Chan PK
    Clin Infect Dis; 2013 Dec; 57(11):1511-9. PubMed ID: 24046309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
    Hayden FG; Sugaya N; Hirotsu N; Lee N; de Jong MD; Hurt AC; Ishida T; Sekino H; Yamada K; Portsmouth S; Kawaguchi K; Shishido T; Arai M; Tsuchiya K; Uehara T; Watanabe A;
    N Engl J Med; 2018 Sep; 379(10):913-923. PubMed ID: 30184455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers.
    Mallory RM; Ali SO; Takas T; Kankam M; Dubovsky F; Tseng L
    Biologicals; 2017 Nov; 50():81-86. PubMed ID: 28844541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.
    Ramos EL; Mitcham JL; Koller TD; Bonavia A; Usner DW; Balaratnam G; Fredlund P; Swiderek KM
    J Infect Dis; 2015 Apr; 211(7):1038-44. PubMed ID: 25281755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
    Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D
    EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study.
    Trevejo JM; Asmal M; Vingerhoets J; Polo R; Robertson S; Jiang Y; Kieffer TL; Leopold L
    Antivir Ther; 2018; 23(4):335-344. PubMed ID: 29244026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers.
    Deleu S; Kakuda TN; Spittaels K; Vercauteren JJ; Hillewaert V; Lwin A; Leopold L; Hoetelmans RMW
    Br J Clin Pharmacol; 2018 Nov; 84(11):2663-2672. PubMed ID: 30098042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.